Context

Valneva is a French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company has been listed on Euronext Paris since 2007 and on Nasdaq since 2021

The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19

Valneva announced positive Phase 3 results of its VLA2001 COVID-19 vaccine, meeting both co-primary endpoints demonstrating superior neutralizing antibody titer levels as well as better tolerability profile compared to active comparator AstraZeneca’s approved Vaxzevria vaccine. On the back of these results, Valneva has commenced rolling submission for initial approval in both the UK and Europe

Proceeds will be mainly used to fund the development of the Lyme VLA15 vaccine candidate through completion of Phase 2, the chikungunya VLA1553 vaccine candidate through BLA approval, the COVID-19 VLA2001 vaccine candidate through conditional licensure, and for working capital and general corporate purposes

About Valneva

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Discover Valneva

Hervé Ronin

Investment Banking

Hervé Ronin senior photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Mickael Dubourd

Investment Banking

Mickael Dubourd photo

Hugo Fischer

Equity Capital Markets

Jonathan Pavillard

Investment Banking

Jonathan Pavillard

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }

Privacy Preference Center